Another immunometabolism deal? Johns Hopkins spinout Dracen lands $36M investment from Deerfield
In the second financing round announced in one day for an immunometabolism startup, Johns Hopkins spinout Dracen Pharmaceuticals just wrapped up a $36 million investment deal from Deerfield.
This money was part of a bigger $40 million Series A round, which got reported before the deal actually closed.
The company, founded just a year ago, is developing novel glutamine antagonists that work as inhibitors of cancer metabolism, choking out tumors and their normal metabolic function.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.